Partnering with us
Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing a range of topically generic products for the US market by leveraging its on-site laboratories, clinical and commercial experience to bring affordable products to market. Acrux has a growing portfolio of FDA approved products including Lidocaine and Prilocaine Cream USP, 2.5%/2.5%. Efinaconazole 10% Solution, Dapsone 5% Gel, Dapsone 7.5% Gel and Nitroglycerin 0.4% Ointment.
Acrux encourages collaboration and is well positioned to discuss partnering and product development.